These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
320 related articles for article (PubMed ID: 26418475)
1. Toll-like receptors as targets for allergen immunotherapy. Aryan Z; Rezaei N Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):568-74. PubMed ID: 26418475 [TBL] [Abstract][Full Text] [Related]
2. Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy. Kirtland ME; Tsitoura DC; Durham SR; Shamji MH Front Immunol; 2020; 11():599083. PubMed ID: 33281825 [TBL] [Abstract][Full Text] [Related]
3. A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Aryan Z; Holgate ST; Radzioch D; Rezaei N Int Arch Allergy Immunol; 2014; 164(1):46-63. PubMed ID: 24853609 [TBL] [Abstract][Full Text] [Related]
4. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Rosewich M; Lee D; Zielen S Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250 [TBL] [Abstract][Full Text] [Related]
5. A novel mannoside-glycocluster adjuvant: Compared in vitro to CpG ODN and MPL and tested in vivo in mouse asthma model. Mäkinen K; Mukherjee C; Leino M; Panchadhayee R; Lehto M; Wolff H; Alenius H; Leino R; Savolainen J Allergol Immunopathol (Madr); 2016; 44(1):9-17. PubMed ID: 26395525 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Subcutaneous and Sublingual Immunotherapy for Allergic Rhinoconjunctivitis and Asthma. Roxbury CR; Lin SY Otolaryngol Clin North Am; 2017 Dec; 50(6):1111-1119. PubMed ID: 28964530 [TBL] [Abstract][Full Text] [Related]
7. Effects of the Toll-like receptor 7 (TLR7) agonist, AZD8848, on allergen-induced responses in patients with mild asthma: a double-blind, randomised, parallel-group study. Leaker BR; Singh D; Lindgren S; Almqvist G; Eriksson L; Young B; O'Connor B Respir Res; 2019 Dec; 20(1):288. PubMed ID: 31856838 [TBL] [Abstract][Full Text] [Related]
8. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma]. Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933 [TBL] [Abstract][Full Text] [Related]
9. Biological effects and clinical efficacy of a topical Toll-like receptor 7 agonist in seasonal allergic rhinitis: a parallel group controlled phase IIa study. Greiff L; Ahlström-Emanuelsson C; Alenäs M; Almqvist G; Andersson M; Cervin A; Dolata J; Lindgren S; Mårtensson A; Young B; Widegren H Inflamm Res; 2015 Nov; 64(11):903-15. PubMed ID: 26342289 [TBL] [Abstract][Full Text] [Related]
10. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285 [TBL] [Abstract][Full Text] [Related]
11. Patient selection for subcutaneous versus sublingual immunotherapy. Larenas-Linnemann D Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):588-95. PubMed ID: 26485098 [TBL] [Abstract][Full Text] [Related]
12. Enhancing the Safety and Efficacy of Food Allergy Immunotherapy: a Review of Adjunctive Therapies. Virkud YV; Wang J; Shreffler WG Clin Rev Allergy Immunol; 2018 Oct; 55(2):172-189. PubMed ID: 29968170 [TBL] [Abstract][Full Text] [Related]
13. Allergen immunotherapy: an update on protocols of administration. Larenas-Linnemann D Curr Opin Allergy Clin Immunol; 2015 Dec; 15(6):556-67. PubMed ID: 26485100 [TBL] [Abstract][Full Text] [Related]
14. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Fonseca DE; Kline JN Adv Drug Deliv Rev; 2009 Mar; 61(3):256-62. PubMed ID: 19167442 [TBL] [Abstract][Full Text] [Related]
15. Potential treatments for food allergy. Albin S; Nowak-Węgrzyn A Immunol Allergy Clin North Am; 2015 Feb; 35(1):77-100. PubMed ID: 25459578 [TBL] [Abstract][Full Text] [Related]
16. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Duechs MJ; Hahn C; Benediktus E; Werner-Klein M; Braun A; Hoymann HG; Gantner F; Erb KJ Pulm Pharmacol Ther; 2011 Apr; 24(2):203-14. PubMed ID: 21195789 [TBL] [Abstract][Full Text] [Related]
17. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Senti G; Johansen P; Haug S; Bull C; Gottschaller C; Müller P; Pfister T; Maurer P; Bachmann MF; Graf N; Kündig TM Clin Exp Allergy; 2009 Apr; 39(4):562-70. PubMed ID: 19226280 [TBL] [Abstract][Full Text] [Related]
18. Emerging drugs for the treatment of perennial allergic rhinitis. Licari A; Castagnoli R; Bottino C; Marseglia A; Marseglia G; Ciprandi G Expert Opin Emerg Drugs; 2016; 21(1):57-67. PubMed ID: 26733401 [TBL] [Abstract][Full Text] [Related]
19. Future forms of immunotherapy. Casale TB; Stokes JR J Allergy Clin Immunol; 2011 Jan; 127(1):8-15; quiz 16-7. PubMed ID: 21094518 [TBL] [Abstract][Full Text] [Related]